NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

A mother of three was blindsided by a cervical cancer diagnosis just days before her 30th birthday — despite experiencing ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

A new report explores the disproportionately high death rate among Black women in the Delta from cervical cancer.

A new research paper was published in Oncoscience's Volume 12 on January 20, 2025, titled "Maternal, delivery and neonatal outcomes in women with cervical cancer. A study of a population database." ...

Here are 5 important questions to ask if you’ve been told you have cervical dysplasia: ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

A new research paper was published in Oncoscience’s Volume 12 on January 20, 2025, titled “Maternal, delivery and neonatal ...

Charleston County Master Deputy Jessica Coston describes how she beat back cervical cancer after her symptoms were initially ...